Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.

Owonikoko TK, Khuri FR.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e395.

PMID:
23714559
[PubMed - in process]
Free PMC Article
2.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

PMID:
22845486
[PubMed - indexed for MEDLINE]
3.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
[PubMed - indexed for MEDLINE]
4.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

PMID:
23107319
[PubMed - indexed for MEDLINE]
5.

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Lim HJ, Crowe P, Yang JL.

J Cancer Res Clin Oncol. 2014 Aug 22. [Epub ahead of print]

PMID:
25146530
[PubMed - as supplied by publisher]
6.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

PMID:
23674493
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

Grunt TW, Mariani GL.

Curr Cancer Drug Targets. 2013 Feb;13(2):188-204. Review.

PMID:
23215720
[PubMed - indexed for MEDLINE]
8.

Differentiating mTOR inhibitors in renal cell carcinoma.

Pal SK, Quinn DI.

Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Review.

PMID:
23433636
[PubMed - indexed for MEDLINE]
9.

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R.

Cell Rep. 2014 Jan 30;6(2):377-87. doi: 10.1016/j.celrep.2013.12.035. Epub 2014 Jan 16.

PMID:
24440717
[PubMed - in process]
Free Article
10.

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.

Slomovitz BM, Coleman RL.

Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Epub 2012 Oct 18. Review.

PMID:
23082003
[PubMed - indexed for MEDLINE]
Free Article
11.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
[PubMed - indexed for MEDLINE]
12.

The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Giudice FS, Squarize CH.

J Carcinog Mutagen. 2013 Aug 2;Suppl 5. pii: 003.

PMID:
25126449
[PubMed]
Free PMC Article
13.

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15. Review.

PMID:
21406469
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

Weigelt B, Warne PH, Downward J.

Oncogene. 2011 Jul 21;30(29):3222-33. doi: 10.1038/onc.2011.42. Epub 2011 Feb 28.

PMID:
21358673
[PubMed - indexed for MEDLINE]
15.

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C.

PLoS One. 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. Epub 2013 Jan 2.

PMID:
23301057
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers.

Houédé N, Pourquier P.

Pharmacol Ther. 2014 Jun 12. pii: S0163-7258(14)00121-1. doi: 10.1016/j.pharmthera.2014.06.004. [Epub ahead of print] Review.

PMID:
24929024
[PubMed - as supplied by publisher]
17.

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.

Ekstrand AI, Jönsson M, Lindblom A, Borg A, Nilbert M.

Fam Cancer. 2010 Jun;9(2):125-9. doi: 10.1007/s10689-009-9293-1.

PMID:
19731079
[PubMed - indexed for MEDLINE]
18.

The mTOR Signalling Pathway in Human Cancer.

Pópulo H, Lopes JM, Soares P.

Int J Mol Sci. 2012;13(2):1886-918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10.

PMID:
22408430
[PubMed]
Free PMC Article
19.

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.

Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.

PMID:
21998291
[PubMed - indexed for MEDLINE]
Free Article
20.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

PMID:
20686178
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk